Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

NCT05081245 is registered in ClinicalTrials.gov with MapLight Therapeutics as lead sponsor.

NCT NCT05081245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05081245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).
Lead sponsor
MapLight Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 13, 2022
Completion date
April 17, 2026
Enrollment
168 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder